Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 28,053 shares at $71.03 ($2.0M) on 2026-02-19, disclosed to the SEC on 2026-02-23.
Scheduled sale ($2.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.03 | 18,923 | $1.3M | 67.1% |
| 2 | $72.08 | 8,528 | $615K | 30.7% |
| 3 | $72.80 | 602 | $44K | 2.2% |
| Total | $71.39 avg | 28,053 | $2.0M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |